Opinion|Videos|September 9, 2024
Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis
Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please review oral JAK inhibitors that are FDA approved for atopic dermatitis (AD) (abrocitinib, upadacitinib).
- Are there any differences in the mechanism of action of FDA-approved JAK inhibitors compared with conventional therapies that are important for prescribers to know?
- Why is treatment with oral JAK inhibitors an attractive option for AD?
- At what point during a patient’s treatment journey would you recommend use of JAK inhibitors?
- How does disease severity affect your recommendation?
- In which patients would you consider using a JAK inhibitor? Please describe characteristics of an ideal patient for oral JAK inhibitor.
Advertisement
Related to this article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.
In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.
Advertisement
Advertisement
Trending on HCPLive
1
The HCPFive: Top News for Healthcare Providers from the Week of 09/13
2
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
3
When Innovation Builds Clinical Confidence: Evaluating Treatment Options in Hemophilia A
4
Zasocitinib NDA Acceptance: What It Means for Psoriasis Treatment
5